Metabolic tumor parameters complement clinicopathological factors in prognosticating advanced stage Hodgkin Lymphoma

Objective(s):Advanced Hodgkin Lymphoma has a higher probability of relapse and recurrence. Classical clinicopathological parameters including the International Prognostic Score (IPS) have not been reliable in predicting prognosis or tailoring treatment. Since FDG PET/CT is the standard of care in st...

Full description

Saved in:
Bibliographic Details
Published in:Asia oceania journal of nuclear medicine and biology 2023-01, Vol.11 (2), p.111-121
Main Authors: Mohite, Ashish, Rangarajan, Venkatesh, Goda, Jayant, Chugh, Swati, Agrawal, Archi, Sengar, Manju
Format: Article
Language:English
Subjects:
18f-fdg pet/ ct
advanced hodgkin’s lymphoma
Bone marrow
Chemotherapy
clinicopathological parameters
event free survival
Hodgkin's lymphoma
Lymphoma
Medical imaging
Medical prognosis
metabolic tumor parameters
Metabolism
Original
Patients
Positron emission tomography
Radiation therapy
Software
Survival
Tomography
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective(s):Advanced Hodgkin Lymphoma has a higher probability of relapse and recurrence. Classical clinicopathological parameters including the International Prognostic Score (IPS) have not been reliable in predicting prognosis or tailoring treatment. Since FDG PET/CT is the standard of care in staging Hodgkin Lymphoma, this study attempted to evaluate the clinical utility of baseline metabolic tumor parameters in a cohort of advanced Hodgkin lymphoma (stage III and IV). Methods: Histology-proven advanced Hodgkin Patients presenting to our institute between 2012-2016 and treated with chemo-radiotherapy (ABVD / AEVD) were followed up till 2019. Quantitative PET/CT and clinicopathological parameters were used to estimate the Event Free Survival (EFS) in 100 patients. Kaplan-Meier method with log-rank test was used to compare the survival times of prognostic factors.Results:At a median follow-up of 48.83 months (IQR:33.31-63.05 months), the five-year-EFS was 81%. Of the 100 patients, 16 had relapsed (16%) and none died at the last follow-up. On Univariate analysis, among non-PET parameters bulky disease (P=0.03) and B-symptoms (P=0.04) were significant while among PET/CT parameters SUVmax (p=0.001), SUVmean (P=0.002), WBMTV2.5 (P
ISSN:2322-5718
2322-5726
DOI:10.22038/AOJNMB.2023.69260.1482